← Back to headlines
Lantheus Receives Complete Response Letter for LNTH-2501
Lantheus Holdings, Inc. has announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for LNTH-2501.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Zamfara Governor Unveils $200 Million Lithium Processing Plant, Targets 2,000 Jobs
22m ago
Lawal unveils $200m lithium processing plant in Zamfara, targets 2,000 jobs
22m ago
Optimism in European corporate earnings could boost stock market
25m ago